Biogen's acquisition of Apellis Pharmaceuticals will add Syfovre and Empaveli to the latter company's portfolio of medicines.

Whether the deal reaches its full value hinges on US regulatory milestones for Centessa’s lead candidate, cleminorexton.

Symeres has partnered with Ambagon Therapeutics on molecular glue research in colorectal cancer to target diseases considered hard to treat.

Telomir Pharmaceuticals has submitted an IND application to the FDA for Telomir-1, its lead candidate targeting advanced and metastatic TNBC.

At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key ...

A lack of effective non-invasive ways to diagnose endometriosis contributes to delayed intervention and limits the potential for clinical development of therapeutics. Credit: H_Ko/Shutterstock.com.

Blackstone says this is the largest private life sciences fund ever raised, which will support innovation in pharma and medtech.

Antibody drug conjugate programs (ADCs) are growing fast in oncology, combining selectivity with high potency.

Otsuka Pharmaceutical is to fully acquire Transcend Therapeutics via its subsidiary Otsuka America for a potential ...

At the 2026 ACC Scientific Session in New Orleans, researchers presented a meta-analysis of three randomized trials (1,264 ...

The UK must tackle commercial, funding and systemic challenges to fully harness its global life sciences, pharma and biotech potential.

Teva Pharmaceutical has announced the US FDA approval for Ponlimsi as a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair by both the agency and the ...